| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a multi-CDK inhibitor with activity against CDK1, CDK2, CDK5, and CDKIt's being investigated for various types of cancers, including hematologic malignancies and solid tumors. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a pan-CDK inhibitor targeting CDK1, CDK2, CDK4, CDK6, CDK7, and CDKIt has been studied in research models for several types of cancers. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a pan-CDK inhibitor that has been studied to inhibit CDK1, CDK2, CDK5, and CDK7. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a CDK2, CDK7, and CDK9 inhibitor. It has been explored for its anticancer activity in both solid tumors and hematologic malignancies. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
LEE011, also known as Ribociclib (different from the Ribociclib mentioned earlier), is a selective CDK4/6 inhibitor. | ||||||
P276-00 | 920113-03-7 | sc-477932 | 1 mg | $380.00 | ||
P276-00 is a novel CDK inhibitor with activity against CDK1, CDK2, CDK4, and CDKIt has shown potential in research studies against various cancers. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
AT7519 is a multi-CDK inhibitor that targets CDK1, CDK2, CDK4, CDK6, CDK7, and CDKIt. | ||||||